Inceptionr LLC Invests $421,000 in Mirum Pharmaceuticals, Inc. $MIRM

Inceptionr LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 1st quarter, Holdings Channel reports. The fund acquired 4,558 shares of the company’s stock, valued at approximately $421,000.

Other large investors have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its stake in shares of Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares in the last quarter. State Street Corp lifted its stake in Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after buying an additional 797,088 shares in the last quarter. Wellington Management Group LLP lifted its stake in Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after buying an additional 672,118 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Mirum Pharmaceuticals by 709.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after buying an additional 536,674 shares during the last quarter. Finally, Voloridge Investment Management LLC increased its position in Mirum Pharmaceuticals by 2,116.6% during the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after buying an additional 371,999 shares in the last quarter.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the sale, the chief financial officer owned 42,181 shares of the company’s stock, valued at $5,156,627.25. This trade represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.27, for a total transaction of $2,445,400.00. Following the sale, the chief executive officer owned 194,309 shares in the company, valued at $23,758,161.43. This represents a 9.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 65,315 shares of company stock worth $6,991,928. 8.32% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $113.03 on Monday. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $50.25 and a fifty-two week high of $130.00. The firm’s 50 day moving average price is $108.77 and its two-hundred day moving average price is $100.52. The stock has a market cap of $6.89 billion, a price-to-earnings ratio of -8.30 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. JPMorgan Chase & Co. raised their price target on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. Morgan Stanley lifted their price target on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Thursday, June 11th. Wolfe Research assumed coverage on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $143.40.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.